Friess Associates’s Allergan plc AGN Stock Holding History

Friess Associates’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,900	Closed	-$2.92M	–	173
2016 Q1	$2.92M	Buy	+10,900	New	+$3.12M	0.29%	78

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Friess Associates's AGN Position: Q2 2016 in Review

Friess Associates sold out of Allergan plc (AGN) in Q2 2016, closing a stake of 10,900 shares — an estimated $2.92M sold.

Friess Associates first reported a position in AGN in Q1 2016 and held it in 1 quarter. The position peaked at $2.92M in Q1 2016. 1,107 funds tracked by Wall St. Rank hold AGN as of Q2 2016.

Friess Associates reported no remaining Allergan plc position as of Q2 2016 after selling out during the quarter.
Friess Associates sold 10,900 Allergan plc shares in Q2 2016, an estimated $2.92M.
Friess Associates first reported a position in Allergan plc in Q1 2016 and held it in 1 quarter.
Friess Associates's Allergan plc position peaked at $2.92M in Q1 2016.
1,107 funds tracked by Wall St. Rank held Allergan plc as of Q2 2016.

Based on Friess Associates's 13F filing for Q2 2016, filed 12 Aug 2016.